Evidence map›Paper›PMID 34425576›Full record

ArticleJournal of innate immunity2022

Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein.

Mostafa Jarahian, Katharina Marstaller, Nadine Banna, Roshanak Ahani, Mohammad Hossein Etemadzadeh, Lea K Boller, Kayhan Azadmanesh, Angel Cid-Arregui, Abdolrahman Khezri, Martin R Berger and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of innate immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Mostafa JarahianToxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Katharina MarstallerToxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nadine BannaToxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Roshanak AhaniDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran.
Mohammad Hossein EtemadzadehDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran.
Lea K BollerDepartment of Immunology, Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany.
Kayhan AzadmaneshDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran.
Angel Cid-ArreguiTargeted Tumor Vaccines Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abdolrahman KhezriDepartment of Biotechnology, Inland Norway University of Applied Sciences, Hamar, Norway.
Martin R BergerToxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Frank MomburgAntigen Presentation and T/NK Cell Activation Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Carsten WatzlDepartment of Immunology, Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany.
German Cancer Research Center · DEPasteur Institute of Iran · IRTU Dortmund University · DEUniversity of Inland Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of the extensively glycosylated Ebolavirus glycoprotein (EBOV-GP) induces physical alterations of surface molecules and plays a crucial role in viral pathogenicity. Here we investigate the interactions of EBOV-GP with host surface molecules using purified EBOV-GP, EBOV-GP-transfected cell lines, and EBOV-GP-pseudotyped lentiviral particles. Subsequently, we wanted to examine which receptors are involved in this recognition by binding studies to cells transfected with the EBOV-GP as well as to recombinant soluble EBOV-GP. As the viral components can also bind to inhibitory receptors of immune cells (e.g., Siglecs, TIM-1), they can even suppress the activity of immune effector cells. Our data show that natural killer (NK) cell receptors NKp44 and NKp46, selectins (CD62E/P/L), the host factors DC-SIGNR/DC-SIGN, and inhibitory Siglecs function as receptors for EBOV-GP. Our results show also moderate to strong avidity of homing receptors (P-, L-, and E-selectin) and DC-SIGNR/DC-SIGN to purified EBOV-GP, to cells transfected with EBOV-GP, as well as to the envelope of a pseudotyped lentiviral vector carrying the EBOV-GP. The concomitant activation and inhibition of the immune system exemplifies the evolutionary antagonism between the immune system and pathogens. Altogether these interactions with activating and inhibitory receptors result in a reduced NK cell-mediated lysis of EBOV-GP-expressing cells. Modulation of these interactions may provide new strategies for treating infections caused by this virus.

Indexed as

EbolavirusGlycoproteinsReceptors, Natural Killer CellSelectinsSialic Acid Binding Immunoglobulin-like LectinsViral Envelope ProteinsGlycoproteinsReceptors, Natural Killer CellSelectinsSialic Acid Binding Immunoglobulin-like LectinsViral Envelope ProteinsEbolavirus glycoproteinHPVNatural cytotoxicity receptorsSelectinsSiglecs

Identifiers

PMID34425576
PMCPMC9082198
OpenAlexW3196008341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.